MEDIA CENTER

Economic Observer Network | Legend Biologics' CAR-T therapy is approved for the first time, but will the 'closed' FDA door be opened?
Frost & Sullivan insights On March 1st, the FDA officially approved Legend Biologics' CAR-T product, which is the first CAR-T therapy in China to receive FDA approval. Affected by this news, Legend Biologics soared by 11.16% after the market closed, with a market value of $6.051 billion. Legendary B
Explore more
CBN | Hong Kong stocks' 18A-listed companies raised over HK$100 billion, what other potential tracks are there in biotechnology
Frost & Sullivan insights In April 2018, the Hong Kong Stock Exchange added Chapter 18A 'Biotechnology Companies' to its Main Board listing rules, allowing biotechnology companies that are not profitable and have no revenue to submit listing applications. Recently, the 'Investment Activity Report on
Explore more
Daily Economic News | From 0 to 48, What Else Does the Hong Kong '18A' Biotech Companies Listing Rule Bring Apart from Facilitating the Listing of Innovative Enterprises?
Frost & Sullivan insights In April 2018, the Hong Kong Stock Exchange added Chapter 18A 'Biotechnology Companies' to its Main Board listing rules, allowing biotechnology companies that have no revenue or profit to submit listing applications. As a result, the Hong Kong Stock Exchange has become the
Explore more
LFYTECH | Digital technology in China's 'Belt and Road' initiative holds promise of becoming a global technical standard in the future
Frost & Sullivan insights According to analysts, the growing technical expertise on China's Digital Silk Road is expected to become a benchmark for other regions around the world to emulate. The Belt and Road Initiative (BRI) in China has already embarked on the digital Silk Road before other parts
Explore more
Securities Daily | Intelligent Connected Vehicles: 'Technological Upgrade + Safety Assurance' Collaborate to Drive Industry Development into Fast Lane
Frost & Sullivan insights In 2021, multiple tech giants such as Baidu and Huawei accelerated the construction of intelligent vehicle ecosystems. Recently, the China Intelligent Connected Vehicle Industry Innovation Alliance and the National Intelligent Connected Vehicle Innovation Center released th
Explore more
Blue Whale Finance | The high difficulty of listing coupled with insufficient source innovation is an embarrassment. Is the 'future has come' for local innovative drugs or has the 'dividend' ended?
Frost & Sullivan insights "Innovation" has become the top keyword in the pharmaceutical industry in 2021. Looking at the approval of new drugs, this year at least 61 new drugs have been approved for marketing by the National Medical Products Administration (NMPA) of China, including 25 locally devel
Explore more
CGTN|Frost & Sullivan Dr. Wang Xin: The Arrival of RCEP May Boost the Upgrading and Transformation of China's Manufacturing Industry
沙利文全球合伙人兼大中华区总裁王昕博士日前接受中国国际电视台《全球财经》(CGTN Global Business)栏目采访,分享对于中国加入RCEP的一系列看法。
Explore more
Securities Daily | Frost & Sullivan Dr. Wang Xin: Shipbuilding will develop towards greener and smarter products, as well as higher-end product structures
沙利文全球合伙人兼大中华区总裁王昕博士接受《证券日报》采访,从“中国神船”重大资产重组看中国造船业的未来发展之路。
Explore more
CGTN | Dr. Wang Xin: The Arrival of RCEP May Assist in the Upgrading and Transformation of China's Manufacturing Industry
Frost & Sullivan insights According to Xinhua News Agency, a recent executive meeting of the State Council was held to determine cross-cycle adjustment measures to promote stable foreign trade development; arrangements were made for the implementation of the Regional Comprehensive Economic Partnersh
Explore more
Bloomberg's 'Brainstorm': Who Can Lead the Future of the New Tea Drink Industry
Frost & Sullivan' The new tea drink market is heating up, with both new and old players vying to enter the market. In this multi-billion-dollar arena, where many competitors compete for dominance, who can stand out? How can brands open up new growth spaces? Recently, the 'Brainstorming' program of C
Explore more
